Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director | June 06, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verrica Pharmaceuticals Inc.
Report date June 06, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2034-06-05 | Direct | 20,000 |
Reported balance
After 2024-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2024 Filed Jun 7, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015958 · form4-06072024_040607.xml · derivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 13:05 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-036151 · doc4.xml · derivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2033-06-07 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:20 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-22-036300 · doc4.xml · derivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:59 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 5,834 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-040269 · doc4.xml · derivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2031-06-09 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 17, 2021 20:33 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 8,109 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041444 · doc4a.xml · derivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Underlying: Common Stock · 8,109 shares Expires 2031-06-09 F1 · shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F1 · balance_after: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 20:40 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 4,772 | $8.57 | $40,896.04 |
DisclosureSEC source: 0001209191-20-048401 · doc4.xml · nonDerivative · entry 2 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.81 inclusive. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 20:40 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 5,228 | $9.16 | $47,888.48 |
DisclosureSEC source: 0001209191-20-048401 · doc4.xml · nonDerivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,228 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.03 to $9.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:50 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantOption Grant (right to buy) · Derivative | 5,834 | $0.00 Strike: $11.38 | $0.00 |
DisclosureSEC source: 0001209191-20-036321 · doc4.xml · derivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2030-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 11, 2020 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:52 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 17,502 | $0.00 Strike: $9.87 | $0.00 |
DisclosureSEC source: 0001209191-19-037165 · doc4.xml · derivative · entry 1 Ballaron Craig · CIK 0001779433 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 17,502 shares Expires 2029-06-13 F1 · derivative.exercise_date: 1/3 of the total shares subject to the option shall vest on June 12, 2020 and 1/36th of the total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.